Literature DB >> 11914026

Total and free insulin-like growth factor I, insulin-like growth factor binding protein 3 and acid-labile subunit reflect clinical activity in acromegaly.

S B Sneppen1, M Lange, L M Pedersen, L Ø Kristensen L, K M Main, A Juul, N E Skakkebaek, U Feldt-Rasmussen.   

Abstract

The aim was to evaluate, markers of disease activity in acromegaly in relation to perceived disease activity. Thirty-seven consecutively treated, acromegalic patients, classified by clinical symptoms as inactive (n=16), slightly active (n=10) and active (n=11), entered the study. When evaluating the inactive and the active groups, we found that positive and negative predictive values (PV(pos), PV(neg)) for clinical disease activity of total and free insulin-like growth factor-I (IGF-I) were 0.59, 0.90 and 1.00, 0.82 respectively. Acid-labile subunit (ALS) showed diagnostic merit similar to insulin-like growth factor binding protein-3 (IGFBP-3) with PV(pos) of 0.69 and 0.71 and PV(neg) of 0.91 and 0.92 respectively. We conclude that free IGF-I is more closely related than total IGF-I to perceived disease activity and is as such useful when evaluating previously treated acromegaly for disease activity. Total IGF-I, IGFBP-3 and ALS possess a higher PV(neg) for the clinical disease activity. None of the parameters can at present be claimed to be superior to the others and thus all the measured parameters are recommended to be part of the evaluation of acromegalic patients. Copyright 2001 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11914026     DOI: 10.1054/ghir.2001.0254

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  2 in total

Review 1.  Serum IGF-I levels in the diagnosis and monitoring of acromegaly.

Authors:  A M Brooke; W M Drake
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

Review 2.  Utility of free IGF-I measurements.

Authors:  Jan Frystyk
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.